Free tool
FAERS Monitor: Epogen/Procrit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103234 or its brand name (Epogen/Procrit, Epoetin Alfa). Reports on generic versions are filed under their own applications.
Reports
32,014
Serious
23,349
73% of reports
Hospitalization
11,822
Death reported
6,846
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3,119
- anaemia2,266
- haemoglobin decreased1,988
- fatigue1,838
- diarrhoea1,557
- nausea1,552
- asthenia1,494
- dyspnoea1,469
- off label use1,416
- product storage error1,292
- pain1,176
- pneumonia1,175
- vomiting1,138
- drug ineffective1,059
- pyrexia970
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 881 |
| 2005 | 934 |
| 2006 | 1,498 |
| 2007 | 1,330 |
| 2008 | 1,200 |
| 2009 | 1,281 |
| 2010 | 1,330 |
| 2011 | 1,150 |
| 2012 | 1,790 |
| 2013 | 1,872 |
| 2014 | 1,474 |
| 2015 | 1,981 |
| 2016 | 1,981 |
| 2017 | 2,027 |
| 2018 | 1,903 |
| 2019 | 1,484 |
| 2020 | 1,224 |
| 2021 | 1,177 |
| 2022 | 1,546 |
| 2023 | 1,352 |
| 2024 | 1,310 |
| 2025 | 813 |
| 2026 | 476 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,145 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemoglobin decreasedSignal | 1,988 | 13.0 | 12.4 | 21,594 |
| product storage errorSignal | 1,292 | 9.8 | 9.3 | 10,126 |
| anaemiaSignal | 2,266 | 7.9 | 7.6 | 13,583 |
| astheniaSignal | 1,494 | 2.6 | 2.5 | 1,512 |
| pneumoniaSignal | 1,175 | 2.4 | 2.3 | 959 |
| deathSignal | 3,119 | 2.4 | 2.3 | 2,601 |
| pyrexia | 970 | 1.8 | 1.7 | 379 |
| dyspnoea | 1,469 | 1.7 | 1.6 | 440 |
| vomiting | 1,138 | 1.6 | 1.5 | 255 |
| diarrhoea | 1,557 | 1.6 | 1.5 | 346 |
| fatigue | 1,838 | 1.6 | 1.5 | 374 |
| nausea | 1,552 | 1.3 | 1.2 | 104 |
| pain | 1,176 | 1.3 | 1.2 | 64 |
| off label use | 1,416 | 1.1 | 1.0 | 5 |
| drug ineffective | 1,059 | 0.5 | 0.5 | 477 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.